Key facts
- Robeauté’s last known valuation is $107.5M (Jan 2025).
- It has raised $32.5M; the latest was Later Stage VC ($28.0M) in Jan 2025.
- Notable investors include MedTech Innovator, La French Tech, Phoenix Court, Cherry Ventures, Kindred Ventures — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Robeauté
- ·The full record, as it builds
Funding rounds
No funding rounds for Robeauté are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Robeauté
Developer of a sub-millimetric medical device designed to diagnose and treat neuropathologies. The company's device is a nanobot that is smaller than a human cell that can enter the brain, navigate through tissues and cells and reach the targeted area without causing trauma, while the nanoelectronics included in the device lets it send critical information back to neuroscientists, enabling neurologists to get a device that can reach the human brain to treat neurological diseases and brain tumors.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2017
- Employees
- 39
- Website
- robeaute.com/
- Ownership
- Privately Held (backing)
Robeauté doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Robeauté shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Robeauté in its N-PORT filings yet. We sweep new filings monthly.